Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.

Core-binding factor (CBF) acute myeloid leukemia (AML) encompasses AML with inv(16)(p13.1q22) and AML with t(8;21)(q22;q22.1). Despite sharing a common pathogenic mechanism involving rearrangements of the CBF transcriptional complex, there is growing evidence for considerable genotypic heterogeneity. We comprehensively characterized the mutational landscape of 350 adult CBF-AML [inv(16): n = 160, t(8;21): n = 190] performing targeted sequencing of 230 myeloid cancer-associated genes. Apart from common mutations in signaling genes, mainly NRAS, KIT, and FLT3, both CBF-AML entities demonstrated a remarkably diverse pattern with respect to the underlying cooperating molecular events, in particular in genes encoding for epigenetic modifiers and the cohesin complex. In addition, recurrent mutations in novel collaborating candidate genes such as SRCAP (5% overall) and DNM2 (6% of t(8;21) AML) were identified. Moreover, aberrations altering transcription and differentiation occurred at earlier leukemic stages and preceded mutations impairing proliferation. Lasso-penalized models revealed an inferior prognosis for t(8;21) AML, trisomy 8, as well as FLT3 and KIT exon 17 mutations, whereas NRAS and WT1 mutations conferred superior prognosis. Interestingly, clonal heterogeneity was associated with a favorable prognosis. When entering mutations by functional groups in the model, mutations in genes of the methylation group (ie, DNMT3A, TET2) had a strong negative prognostic impact.

[1]  W. Hiddemann,et al.  The clinical mutatome of core binding factor leukemia , 2020, Leukemia.

[2]  B. Ebert,et al.  Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1) , 2019, Leukemia.

[3]  L. Bullinger,et al.  Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. , 2019, Blood.

[4]  Christopher A. Miller,et al.  Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential , 2018, Nature Communications.

[5]  Karl W. Kroll,et al.  Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia , 2017, Leukemia.

[6]  Eunhee Kim,et al.  ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia , 2017, Nature Communications.

[7]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[8]  Heather L. Mulder,et al.  The genomic landscape of core-binding factor acute myeloid leukemias , 2016, Nature Genetics.

[9]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[10]  W. Hiddemann,et al.  ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation , 2016, Nature Communications.

[11]  O. Abdel-Wahab,et al.  Comprehensive mutational profiling of core binding factor acute myeloid leukemia. , 2016, Blood.

[12]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[13]  W. Kahr,et al.  Dynamin 2‐Dependent Endocytosis is Required For Normal Megakaryocyte Development , 2015, Blood.

[14]  Jun Huang,et al.  The Human SRCAP Chromatin Remodeling Complex Promotes DNA-End Resection , 2014, Current Biology.

[15]  T. Haferlach,et al.  High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome , 2014, Leukemia.

[16]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[17]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[18]  K. Döhner,et al.  Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. , 2009, Blood.

[19]  A. Sorkin,et al.  Endocytosis and signalling: intertwining molecular networks , 2009, Nature Reviews Molecular Cell Biology.

[20]  Karl Pearson F.R.S..  X. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling , 2009 .

[21]  C. Bloomfield,et al.  Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study , 2008 .

[22]  Thomas A Gerds,et al.  Efron‐Type Measures of Prediction Error for Survival Analysis , 2007, Biometrics.

[23]  Harald Binder,et al.  Assessment of survival prediction models based on microarray data , 2007, Bioinform..

[24]  C. Bloomfield,et al.  Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Dombret,et al.  Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) , 2006, Leukemia.

[26]  C. Bloomfield,et al.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Thomas Augustin,et al.  Bradley-Terry-Luce models to incorporate within-pair order effects: representation and uniqueness theorems. , 2004, The British journal of mathematical and statistical psychology.

[28]  K. Döhner,et al.  Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Shiekhattar,et al.  Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. , 2003, Molecular cell.

[30]  J. Reilly,et al.  Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias , 2003, British journal of haematology.

[31]  J. Downing,et al.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. , 2002, Cancer cell.

[32]  N. Jenkins,et al.  Mga, a dual‐specificity transcription factor that interacts with Max and contains a T‐domain DNA‐binding motif , 1999, The EMBO journal.

[33]  Lisa Garrett,et al.  The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia , 1999, Nature Genetics.

[34]  Y. Ito,et al.  Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Tibshirani.  The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.

[36]  M. Akritas.  Nearest Neighbor Estimation of a Bivariate Distribution Under Random Censoring , 1994 .

[37]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.

[38]  F. Ferrara,et al.  Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. , 2006, Blood.

[39]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .